Clinical Trial Update: Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pharmacokinetics and safety of rifabutin 150 mg daily versus 300 mg thrice weekly in HIV and tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• RIFABUTIN (Rifabutin)

Snippet

Sponsor: The HIV Netherlands Australia Thailand Research Collaboration | Conditions: HIV, Tuberculosis | Phase 2 | Status: COMPLETED